Delta-Fly Pharma, Inc. ((JP:4598)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Delta-Fly Pharma, Inc. is conducting a Phase I/II clinical study titled ‘Phase I/II Study of DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia.’ The study aims to evaluate the safety and preliminary efficacy of combining DFP-10917 with venetoclax for treating relapsed or refractory acute myeloid leukemia, a significant step in advancing treatment options for this challenging condition.
The study tests the experimental drugs DFP-10917 and venetoclax. DFP-10917 is administered as a continuous intravenous infusion, while venetoclax is given orally. Both drugs aim to improve treatment outcomes for patients with acute myeloid leukemia.
This interventional study is non-randomized with a parallel assignment model and no masking, focusing primarily on treatment. The study is designed to assess safety and efficacy in a structured manner, progressing from initial safety evaluations to broader efficacy assessments.
The study began on April 19, 2024, with primary completion expected by August 31, 2025, and the last update submitted on the same date. These timelines are crucial for tracking the study’s progress and potential market entry.
The study’s progress could influence Delta-Fly Pharma’s stock performance, as positive results may boost investor confidence and interest. The competitive landscape in leukemia treatment is evolving, and advancements in this study could position Delta-Fly Pharma favorably against competitors.
The study is ongoing, with further details available on the ClinicalTrials portal.